Ascendis Pharma A/S (A710)
Munich
Closed
Aug 25, 2026
Day's Range
217.1052 wk Range
181.64Overview - A710 - Ascendis Pharma A/S
Key Statistics
Valuation
Enterprise Value
255.74M
P/E (Trailing)
‪-57.96‬
PEG Ratio
‪0.07‬
Price / Book
‪27.54‬
EV / EBITDA
‪-3.84‬
Profitability
Gross Margin
‪92.89%‬
Profit Margin
‪86.81%‬
Operating Margin
‪-18.33%‬
Return on Assets
‪-17.50%‬
Return on Equity
‪140.05%‬
Ownership
Shares Outstanding
61.77M
Price stats
50-Day Avg
‪220.46‬
200-Day Avg
‪213.40‬
Peers - A710 - Ascendis Pharma A/S
Peer Comparison
Compared with companies in Biotechnology listed on Munich.
- A710MunichAscendis Pharma A/S+5.94%52-week change-57.97P/E (Trailing)‪86.81%‬Profit Margin
- 0QFMunichModerna, Inc.+81.73%52-week change25.19P/E (Trailing)‪-141.42%‬Profit Margin
- 4E2MunichRelmada Therapeutics Inc.+86.82%52-week change-2.80P/E (Trailing)—Profit Margin
- 42ZMunichRevolution Medicines Inc.+82.82%52-week change-30.32P/E (Trailing)—Profit Margin
- 5JA1MunichSprint Bioscience AB+82.07%52-week change0.28P/E (Trailing)‪92.17%‬Profit Margin
- B9B9P0MunichNovabay Pharmaceuticals Inc. R+80.00%52-week change-0.01P/E (Trailing)—Profit Margin
- 87EMunichDianthus Therapeutics Inc.+78.62%52-week change-22.50P/E (Trailing)—Profit Margin
Profile Summary - A710 - Ascendis Pharma A/S
About
Ascendis Pharma A/S is a biopharmaceutical company that develops and commercializes therapies for patients with unmet medical needs, with a primary focus on endocrinology and rare diseases. Headquartered in Hellerup, Denmark and founded in 2006, the company uses its TransCon technology platform to modify existing drug…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
